Cargando…

Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability

The elicitation of broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (Env) trimer remains a major vaccine challenge. Most cross-conserved protein determinants are occluded by self-N-glycan shielding, limiting B cell recognition of the underlying polypeptide surface. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubrovskaya, Viktoriya, Tran, Karen, Ozorowski, Gabriel, Guenaga, Javier, Wilson, Richard, Bale, Shridhar, Cottrell, Christopher A., Turner, Hannah L., Seabright, Gemma, O’Dell, Sijy, Torres, Jonathan L., Yang, Lifei, Feng, Yu, Leaman, Daniel P., Vázquez Bernat, Néstor, Liban, Tyler, Louder, Mark, McKee, Krisha, Bailer, Robert T., Movsesyan, Arlette, Doria-Rose, Nicole A., Pancera, Marie, Karlsson Hedestam, Gunilla B., Zwick, Michael B., Crispin, Max, Mascola, John R., Ward, Andrew B., Wyatt, Richard T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891888/
https://www.ncbi.nlm.nih.gov/pubmed/31732167
http://dx.doi.org/10.1016/j.immuni.2019.10.008
Descripción
Sumario:The elicitation of broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (Env) trimer remains a major vaccine challenge. Most cross-conserved protein determinants are occluded by self-N-glycan shielding, limiting B cell recognition of the underlying polypeptide surface. The exceptions to the contiguous glycan shield include the conserved receptor CD4 binding site (CD4bs) and glycoprotein (gp)41 elements proximal to the furin cleavage site. Accordingly, we performed heterologous trimer-liposome prime:boosting in rabbits to drive B cells specific for cross-conserved sites. To preferentially expose the CD4bs to B cells, we eliminated proximal N-glycans while maintaining the native-like state of the cleavage-independent NFL trimers, followed by gradual N-glycan restoration coupled with heterologous boosting. This approach successfully elicited CD4bs-directed, cross-neutralizing Abs, including one targeting a unique glycan-protein epitope and a bNAb (87% breadth) directed to the gp120:gp41 interface, both resolved by high-resolution cryoelectron microscopy. This study provides proof-of-principle immunogenicity toward eliciting bNAbs by vaccination.